Friday, June 16, 2017

Guselkumab at the 2017 EULAR Annual Meeting in Madrid

You might never have heard about guselkumab, which targets IL-23. Other
MABs targeting IL-23 include briakinumab (nothing at the EULAR 2017 meeting), tildrakizumab
(nothing at the EULAR 2017 meeting), and ustekinumab (already available as
Stelara). To be more specific: guselkumab (GUS) is a fully human monoclonal
antibody (MAB) against the p19 subunit of IL-23.

It’s still too early to do projections into the future. A word of
warning however: we had hardly any options to treat psoriatic arthritis for
long time, now we see a proliferation of different principles. Psoriatic
arthritis is less common than rheumatoid arthritis; PsA has a prevalence of
0.16-0.25 % and RA 0.5-1.0 % [2]. Though we are happy for any new therapeutic
principle, we shall have a long way to put all the options into a working
algorithm.

DisclaimerThe author of this blog makes no guarantee as to, and assumes no responsibility for, the correctness, sufficiency or completeness of any and all information or recommendations. The reader is advised to consult his doctor regarding all aspects of individual health care. The information on this blog should not be considered to be a personal medical advice; this blog should be used for informational purposes only.